Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.
Focal therapy targets may potentially reduce adverse events and provide better cancer control, but previous studies have been limited in scope.
According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.
Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.
Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.
Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
The impact of USPSTF recommendations on the incidence and management of prostate cancer have not yet been fully explored.
Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.
Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.
The BMH online survey allows patients to enter comorbidity data at home prior to consultation.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.
The cause of death was prostate cancer among 18% vs 22% of patients receiving ADT vs ADT plus MP, respectively.
Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers
- Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma
- Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer